Quantcast
Last updated on April 17, 2014 at 12:39 EDT

Latest Macular degeneration Stories

2013-11-28 23:00:44

HIMS Inc. announced this week that they will offer deep holiday discounts as well as a new 5% year-round military discount on CANDY and CANDY GRIP portable and handheld video magnifiers and also on LifeStyle HD 22" desktop video magnifier. Austin, TX (PRWEB) November 28, 2013 HIMS Inc., a major manufacturer and distributor of products for those with vision-loss due to Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma or Cataracts has announced several new discount...

2013-11-27 23:03:53

Research presented at the recent American Academy of Optometry (AAO) meeting reveals the powerful clinical utility of the Diopsys® NOVA-VEP Vision Testing System in the assessment of traumatic brain injury (TBI). Pine Brook, NJ (PRWEB) November 27, 2013 SUNY Eye Institute, in conjunction with the SUNY College of Optometry, presented two posters on the use of visual evoked potential (VEP) for evaluating traumatic brain injury (TBI) patients at Academy 2013 Seattle, the AAO’s annual...

2013-11-26 16:24:25

A "Bionic Eye" for Leading Cause of Blindness in Americans Over Age 65 WASHINGTON, Nov. 26, 2013 /PRNewswire-USNewswire/ -- A tiny device is making a big difference in the lives of people with end-stage macular degeneration (AMD), the leading cause of blindness in people over the age of 65 according to the Centers for Disease Control and Prevention. (Photo: http://photos.prnewswire.com/prnh/20131126/DC19365) "Macular degeneration is a disease of the retina where there is a change...

2013-11-25 23:01:47

Dr. Steven Schoenbart, Founder and Owner of Schoenbart Vision Care, who marks five years in his Garden City, NY office and 25 in the industry this month, says anyone who greets him with a “high five” hand salute will enjoy savings on the purchase of certain high end eyeglass frames. Garden City, NY (PRWEB) November 25, 2013 For Dr. Steven Schoenbart, the month of November 2013 marks 25 years in the eye care industry and 5 years at his current office -- and he’s looking to celebrate...

2013-11-22 04:20:56

TARRYTOWN, N.Y., Nov. 22, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO) from the Japanese Ministry of Health, Labour and Welfare. "We are pleased with the approval of EYLEA in Japan in the macular edema following CRVO indication, a significant cause of visual impairment in adults," said George D....

2013-11-21 08:27:15

Many leading causes of adult-onset vision loss can be prevented TORONTO, Nov. 21, 2013 /CNW/ - According to the World Health Organization, 75 per cent of vision loss can be prevented or treated.(i) Today CNIB is launching a national campaign called "Worth a thousand words: Preserve your vision" to raise awareness of the impact of adult-onset vision loss and that many conditions are preventable if diagnosed and treated at an early stage. The campaign features a unique photo...

2013-11-14 12:27:23

MIAMI, Nov. 14, 2013 /PRNewswire-USNewswire/ -- People who went blind as a result of certain diseases or injuries may have renewed hope of seeing again thanks to a retinal implant developed with the help of Florida International University's W. Kinzy Jones, a professor in the College of Engineering and Computing. A tiny video camera mounted on special glasses captures the scene in the patient's environment, and a pocket controller relays the captured video signal to the implant....

2013-11-12 16:26:04

Detailed results from the Phase 3 VIBRANT trial of EYLEA in Macular Edema following Branch Retinal Vein Occlusion (BRVO) to be presented TARRYTOWN, N.Y., Nov. 12, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from several studies of EYLEA(®) (aflibercept) Injection will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 16-19 in New Orleans. EYLEA presentations will be featured during the...

2013-11-07 12:29:22

LEUVEN, Belgium, November 7, 2013 /PRNewswire/ -- - JETREA(R)slowly continues to gain acceptance with the US retina community. - Company increasing US medical education efforts: increasing number of US-based Medical Science Liaison managers to 12. - US Organizational update: Dr Keith Steward appointed Head of US Business Operations. - Benefits of JETREA(R), particularly in early stage patients, confirmed by...

2013-11-07 08:30:54

TARRYTOWN, N.Y., Nov. 7, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in the European Union (EU) for EYLEA(®) (aflibercept) Injection for the treatment of patients with Diabetic Macular Edema (DME). Regeneron has submitted a supplemental BLA for EYLEA in this indication to the U.S. Food and Drug Administration (FDA). "Diabetes is a growing,...